BLTENasdaqPharmaceutical PreparationsFiscal year ends December 31
BELITE BIO, INC
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$147.34+4.56 (+3.19%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 106.8% | -16.9% | |
| Return on assets | – | – | -16.6% | |
| Current ratio | – | – | 50.02 | |
| Interest coverage | – | -273.5× | -42104.0× | |
| Diluted shares | – | 9M | 34M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Belite Bio generated $114.99M from operations and spent $718.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$114.99M
Used
$718.00K
Capital expenditure$718.00K100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$77.61M
- Cash generatingOperating cash flow above zero-$36.99M
- Return on assets improvedROA up on the prior year-38.2% → -51.0%
- Earnings backed by cashOperating cash flow above net income-$36.99M vs -$77.61M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose24.31 → 50.02
- No dilutionShare count did not rise31M → 34M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –